Skip to main content
Ikonisys S.A. logo

Ikonisys S.A. — Investor Relations & Filings

Ticker · ALIKO ISIN · FR00140048X2 LEI · 9695000B742KPNDQ4D05 PA Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2024-05-24 Report Publication Anno…
Country FR France
Listing PA ALIKO

About Ikonisys S.A.

https://www.ikonisys.com

Ikonisys S.A. is a cell-based diagnostics company specializing in Fluorescence in Situ Hybridization (FISH) technology for genetic analysis. The company develops, manufactures, and markets integrated solutions that include proprietary automated microscopy instruments, advanced software, and reagents. These systems are designed to improve efficiency, accuracy, and standardization for pathologists and laboratory technicians. Ikonisys's technology enables the precise detection and analysis of chromosomal alterations, supporting early and accurate cancer diagnosis, prognosis, and the selection and monitoring of personalized therapies. The platform's automation and digitization features streamline the entire workflow from image acquisition to quantitative interpretation for oncology and genetic testing applications.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 100% confidence The document is a press release from Ikonisys SA announcing a delay in the publication of its 2023 annual financial report, which was supposed to be audited. The key phrase is "Ikonisys annonce le report de la publication de son rapport financier annuel 2023" (Ikonisys announces the postponement of the publication of its 2023 annual financial report). This document is not the Annual Report (10-K) itself, nor is it the comprehensive Interim Report (IR). It is an announcement *about* the publication timing of a report. According to Rule 2, if a document is short and announces the publication/delay of a report, it should be classified as a Report Publication Announcement (RPA). The document explicitly states the new expected publication date (June 28, 2024) and provides context, fitting the definition of RPA: 'Announcement regarding the timing, release, or publication of company reports.'
2024-05-24 French
Inside Information / Other news releases
Report Publication Announcement Classification · 100% confidence The document is a press release titled "Ikonisys announces postponement of the publication of its 2023 annual financial report." It explicitly states that the publication of the annual financial report is postponed until June 28, 2024. This document is not the report itself (10-K or IR), but rather an announcement about the timing of a future report's release. According to Rule 2, when a document announces the publication or timing of a report, it should be classified as a Report Publication Announcement (RPA). The document length (4150 chars) is consistent with a brief announcement rather than a full annual report.
2024-05-24 English
Inside Information / Other news releases
M&A Activity Classification · 99% confidence The document is a press release dated May 21, 2024, announcing a new distribution partnership between Hospitex (a subsidiary/related entity of Ikonisys SA) and Diagen LLC in Ukraine. It details a business development, strategic alliance, and mentions revenue contribution to H1 2024. This type of announcement, focusing on business operations, partnerships, and strategic updates rather than mandatory financial reporting (like 10-K, IR, ER), typically falls under general corporate news. Since there is no specific category for 'Partnership Announcement' or 'Business Update', and it is not a formal regulatory filing like a 10-K or a specific financial report, the most appropriate fallback category is 'Regulatory Filings' (RNS) for general corporate announcements that don't fit elsewhere, although 'RPA' (Report Publication Announcement) is sometimes used for press releases, RNS is the broader regulatory/news fallback. Given the content is a news announcement about a business deal, RNS is the best fit among the provided options as a general regulatory/news disclosure.
2024-05-21 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated May 21, 2024, announcing a new distribution partnership between Hospitex and Diagen LLC in Ukraine. It details a business development (expansion into a new market) and includes quotes from management (CEO and General Manager). This type of announcement, focusing on strategic business updates, partnerships, and operational milestones, is characteristic of an Earnings Release (ER) if it were summarizing financial results, or a Regulatory Filing (RNS) if it were a general announcement. However, since it is a formal press release detailing a significant business development (partnership/expansion) and includes financial context (first delivery contributing to H1 2024 revenue), it most closely aligns with an Earnings Release (ER) which often includes operational highlights alongside preliminary financial context, or a general Regulatory Filing (RNS). Given the content is a specific business announcement rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT), and it is not explicitly a notice of dividend (DIV) or management change (MANG), the most appropriate classification among the specific options is ER, as these press releases often accompany or precede formal earnings reports, or RNS as a general regulatory announcement. Since it is a specific business development announcement, RNS is the safest general category, but ER often covers these strategic updates. Given the structure and content (business update, management quotes, date/time stamp), it functions as an Earnings Release or a general announcement. I will classify it as RNS as it is a general corporate announcement that doesn't fit the highly specific financial report codes, but I acknowledge it shares characteristics with ER.
2024-05-21 French
Inside Information / Other news releases
Regulatory Filings Classification · 90% confidence The document is a press release dated May 15, 2024, announcing that Hospitex International obtained an international patent for the BLOCKfast cyto-inclusion kit, which is related to Ikonisys's technology. This is a specific corporate announcement regarding intellectual property and commercial development, not a comprehensive financial report (like 10-K or IR), a management discussion (MDA), or a standard earnings release (ER). It is a specific update that doesn't fit the definitions for AGM-R, DVA, DLST, DIRS, SR, FS, CGR, IRAT, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. It is too specific for a general Regulatory Filing (RNS). Since it relates to a significant business development (patent acquisition) that impacts future operations and market position, it is best classified as a general corporate announcement. Given the provided categories, the closest fit for a specific, non-financial, non-management, non-legal, non-dividend announcement that is not a presentation or transcript is often the general Regulatory Filings (RNS) if no other category applies, or potentially a general announcement. However, since it is a specific announcement about a patent and commercial prospects, and it is not a presentation (IP) or a transcript (CT), it falls under the general regulatory/corporate announcement umbrella. Since there is no specific 'Intellectual Property Announcement' code, RNS (Regulatory Filings) serves as the appropriate fallback for specific, non-standard corporate news releases that are not explicitly defined elsewhere.
2024-05-15 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated May 15, 2024, announcing that Hospitex International (a partner/related entity of Ikonisys SA) has obtained an international patent for the BLOCKfast cytoinclusion kit. This type of announcement, detailing a specific operational or legal development (like patent acquisition) that is not a full financial report (10-K, IR), earnings release (ER), or management discussion (MDA), fits best under the general category for regulatory or significant corporate announcements that don't have a more specific code. Since it is a specific corporate update that is not explicitly covered by codes like DIV, CAP, or MANG, and it is not a formal regulatory filing like a 10-K or a report publication announcement (RPA), the most appropriate fallback is Regulatory Filings (RNS) for significant, non-standard corporate news releases.
2024-05-15 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.